<DOC>
	<DOCNO>NCT00796185</DOCNO>
	<brief_summary>The purpose study compare steady-state pharmacokinetics paliperidone oral administration 15 mg extended-release ( ER ) OROS paliperidone daily steady-state pharmacokinetics paliperidone oral administration 8 mg immediate-release ( IR ) risperidone twice daily ; explore dose-proportionality 9 mg 15 mg ER OROS paliperidone . Other objective 1 ) document disposition enantiomer paliperidone ; 2 ) explore relationship genotype ( CYP2D6 , CYP3A4 , CYP3A5 , UGT1A1 , UGT1A6 ) pharmacokinetic parameter ; 3 ) ass safety tolerability .</brief_summary>
	<brief_title>As Study Pharmacokinetics Paliperidone Extended-release Risperidone Immediate-release Formulations</brief_title>
	<detailed_description>This open-label , multiple-dose , parallel-group study patient schizophrenia schizoaffective disorder . The study consist screen period ( 2 week maximum ) ; 1-week run-in washout ( Days 1 7 ) patient take risperidone prestudy randomly assign paliperidone treatment receive replacement antipsychotic therapy , patient continue take prestudy antipsychotic medication ; 14-day open-label treatment period ( Days 8 21 ) ; 5-day follow-up period . On Day 1 washout period , eligible patient randomize receive ER OROS paliperidone ( PAL ) risperidone ( RIS ) . All patient receive first dose study medication Day 8 randomization follow : Patients randomize PAL receive 9 mg ER OROS paliperidone daily Day 8 Day 14 , follow 15 mg ER OROS paliperidone q.d . Day 15 Day 21 . Patients randomized RIS receive dose-escalation 7 mg risperidone twice daily ( b.i.d . ) Day 8 Day 14 , follow 8 mg risperidone b.i.d . Day 15 Day 21 . The study medication Days 14 21 PAL group Day 21 RIS group administer completion standardize high fat , high caloric breakfast . Patients confine test facility morning Day 8 ( early discretion investigator ) completion study procedure Day 23 . On assessment day , patient return test facility remain duration assessments.The high dose paliperidone currently study 12 mg give 6 tablet 2 mg ER OROS paliperidone . In currently propose study , data safety tolerability 15-mg dose monitor collect . Paliperidone ER oral administration 9 mg q.d . Day 8 14 , 15 mg daily Day 15 21 ; oral administration escalate dos 7 mg risperidone twice daily ( b.i.d . ) Days 8 14 , inclusive , 8 mg risperidone b.i.d . Day 15 21</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Currently treat dose least 6 mg risperidone daily equivalent antipsychotic medication combination thereof ( equivalence table provide site ) Has DSMIV diagnosis schizophrenia ( 295.10 , 295.20 , 295.30 , 295.60 , 295.90 ) schizoaffective disorder Healthy basis prestudy physical exam , medical history , ECG , laboratory result blood biochemistry , hematology , urinalysis perform within 2 week randomization . If result biochemistry hematology test urinalysis within laboratory 's reference range patient include investigator judge deviation clinically significant . For liver function test ( alanine transaminase , aspartate transaminase , bilirubin ) , value must contain within 2 time upper limit normal laboratory reference range renal function test , value must within normal laboratory reference range Women must postmenopausal least 1 year , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization discretion investigator , total abstinence ) entry throughout study , well negative serum pregnancy test screening . To ensure continued eligibility , woman must negative urine test baseline Body weight define body mass index ( weight [ kg ] /height ( ) ² ) within range 15.0 35.0 kg/m² , inclusive Willingness spend 15 day inpatient treatment period Normotensive screening , supine ( 5 minute ) blood pressure range 100 140 mmHg systolic , inclusive , 60 90 mmHg diastolic , inclusive . Involuntarily commit inpatient Has DSMIV diagnosis substance dependence within 3 month screen evaluation . Nicotine caffeine dependence history recreational use marijuana exclusionary At screening , decrease &gt; = 20 mmHg systolic blood pressure decrease &gt; =10 mmHg decrease diastolic blood pressure 2 minute stand , experience symptom lightheadedness , dizziness , faint upon stand orthostatic hypotension Tests positive urine drug screen screen Had acute exacerbation psychotic symptom within last 3 month screen Relevant history current presence cardiovascular , respiratory , central nervous system , neuropsychiatric ( include seizure ) , renal , hepatic , endocrine , immunologic disease Has DSMIV Axis I diagnosis schizophrenia schizoaffective disorder Suicidal homicidal ideation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Paliperidone ER</keyword>
</DOC>